Wednesday , March 29 2017
Home / Precision Medicine

Precision Medicine

Bristol-Myers Collaborates with Parker Institute and CRI for Immuno-Oncology Research

NEW YORK & SAN FRANCISCO–(BUSINESS WIRE)–The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely …

Read More »

Protein Identified as Potential Druggable Target for Pancreatic Cancer

A protein known as arginine methyltransferase 1 (PRMT1) may be a potential therapeutic target for pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, and one of the most deadliest with a less than 10 percent, five-year survival rate. PRMT1 is involved in a number of genetic processes …

Read More »

Vertex’s Cystic Fibrosis Combo Meets Primary Endpoints in Two Late-Stage Studies

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from two Phase 3 studies of the tezacaftor (VX-661) / ivacaftor combination treatment that showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in people with cystic fibrosis (CF) ages 12 and older …

Read More »

New Era in Precision Medicine for Pancreatic Cancer

The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK. The investment will support the PRECISION Panc* project which aims to develop …

Read More »

Regeneron, UK Biobank and GSK Enter Gene Sequencing Initiative

TARRYTOWN, N.Y., March 22, 2017 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research initiative among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain …

Read More »

AML Study Correlates Gene Mutations with 34 Disease Subgroups

Columbus, Ohio – A large, new study of adults with acute myeloid leukemia (AML) correlates 80 cancer-related gene mutations with five subtypes of AML, which are defined by the presence of specific chromosomal abnormalities. Led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer …

Read More »

Three Harvard Experts Explain how Economics Can Shape Precision Medicines

Author affiliations: Harvard Business School, Harvard Medical School, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Kennedy School Many public and private efforts focus on research in precision medicine, the process by which genomic information and other characteristics of a patient’s disease are used to predict which treatments will be most effective. …

Read More »

AstraZeneca’s PARP Inhibitor Lynparza Demonstrates Positive Results in Late-Stage Ovarian Cancer Study

AstraZeneca today presented results from the Phase III SOLO-2 trial demonstrating a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator …

Read More »

FDA Accepts Advaxis’ IND for Amgen-Partnered Personalized Cancer Immunotherapy

PRINCETON, N.J., March 06, 2017 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has indicated the Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in …

Read More »

Scientists Discover New Mechanism that Leads to Inflammation in Rheumatoid Arthritis

New research findings published in the Journal of Leukocyte Biology, suggest that synovial CD4+ T cells that produce IL-21 contribute to joint inflammation by activating synovial fibroblasts in rheumatoid arthritis patients. Understanding the mechanisms of inflammation in rheumatoid arthritis is important for the design of new therapies for this disease. …

Read More »